On March 27, 2024, the Farmak international office successfully completed the acquisition of Symphar, becoming a 100% owner of the Polish pharmaceutical company.
This acquisition is part of the implementation of the international expansion strategy "Pharmac 2.0.: From local success to global success". The deal is the next step after last year's acquisitions in the Czech Republic and Slovakia. It increases Farmak's market share and strengthens its position in the diabetology, nervous system and women's health segments in the EU.
The agreement is the result of careful preparation and evaluation of various options on the Polish market. The acquired business fully meets the requirements of the law and the high ethical and corporate standards of Farmak. The closing took place after the fulfillment of the terms of the agreement and the relevant regulatory procedures.
About "Farmak"
Pharmaceutical company Farmak works with an emphasis on research and development, production, global sales and marketing of generic drugs. By developing its own production and R&D facilities in Ukraine and Spain, "Farmak" has achieved a significant global presence of its products. The company has 10 commercial offices strategically located in various regions of the world, including Ukraine, Poland, the Czech Republic, Slovakia, Central Asia, Asia-Pacific, the Middle East and Western Europe. This extensive network underlines Farmak's commitment to providing access to quality medicines worldwide.
About Symphar
Symphar is a Polish pharmaceutical marketing company with an office in Warsaw. Its team of 90 professionals works with more than 50 products in the fields of diabetology, gynecology, psychiatry and neurology. In 2023, Symphar achieved revenue of more than €22 million as a result of a long period of stable and profitable growth.
Adviser
Investment banking company FinPoint acted as the exclusive financial advisor to Farmak regarding this acquisition.
Swiss Merchant Corporation SA, a Swiss investment and consulting company, acted as the exclusive financial advisor to the seller.
https://farmak.ua/news
